Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB19347ApprovedInvestigationalVaccines

Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 20A individually conjugated to... The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

First approval
Canada, 2024 · United States, 2024
Brand names
  • Capvaxive

Resolves to

Compound
UNIIQ7FD7W9Y87
Clinical / RWD
RxNorm2686920

What you can answer from here — as of August 01, 2026

6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2Marketed productsAcross 2 countries and 2 labellers
Sign in

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In